An option to modify the progressive course of Parkinson’s
Related Stories
![logo](https://udic.es/wp-content/uploads/2017/07/logo.png)
![logo](https://udic.es/wp-content/uploads/2017/07/logo.png)
![logo](https://udic.es/wp-content/uploads/2017/07/logo.png)
21 de November de 2023
Trial on LRRK2 mutation in Parkinson’s disease is about to be completed. Our Clinical Trials…
Posted in: Uncategorised
![logo](https://udic.es/wp-content/uploads/2017/07/logo.png)
8 de May de 2023
Highly positive results from the pivotal Phase III BouNDless trial evaluating ND0612 in patients with…
Posted in: Parkinson
![logo](https://udic.es/wp-content/uploads/2017/07/logo.png)
8 de May de 2023
The new formulation of inhaled levodopa, Inbrija, has been approved for marketing in Spain. Manufactured…
Posted in: Parkinson
![Area privada5](https://udic.es/wp-content/uploads/2017/11/Area-privada5-262x201.jpg)
16 de January de 2023
On Epiphany, the U.S. Food and Drug Administration approved a new drug for early-stage Alzheimer’s…
![Udichome3](https://udic.es/wp-content/uploads/2017/09/Udichome3-262x201.jpg)
8 de June de 2021
The Hospital Universitari General de Catalunya, through the Clinical Research Unit (UDIC), has included the…
Posted in: News
![Area privada5](https://udic.es/wp-content/uploads/2017/11/Area-privada5-262x201.jpg)
8 de June de 2021
The Hospital Universitari General de Catalunya, which was the first center in Spain activated for…
Posted in: News